CSL Shares Jump 18% as Biotech Giant Signals Turnaround Despite US$7.1B Writedowns
Synopsis
CSL's shares rallied after the company outlined its turnaround strategy, launched a new US$1.1 billion buyback and projected stronger profit growth for FY27 despite reporting significant impairment charges.
CSL shares surged 18% after the Australian biotechnology giant reported its FY26 results and reassured investors that its turnaround plan is gaining momentum.
The rally came despite the company posting a statutory net loss of US$2.6 billion driven by US$7.1 billion in pre-tax impairments and US$799 million in restructuring costs.
Investors welcomed the absence of further earnings downgrades alongside a new US$1.1 billion share buyback and guidance for 5% underlying net profit growth in FY27.
For the year ended June 30, CSL reported underlying net profit of US$3.1 billion, down 2% from the previous year, on revenue of US$15.8 billion.
The company said the difficult year marked a reset with management focused on restoring profitability and rebuilding shareholder confidence after months of declining share prices.
Turnaround Strategy Begins to Take Shape
Interim CEO Gordon Naylor said CSL had taken decisive steps to simplify operations and position the business for sustainable growth. The company highlighted strong demand for plasma therapies and encouraging momentum from newer treatments including ANDEMBRY and HEMGENIX.
Chairman Dr Brian McNamee acknowledged shareholder frustration following a challenging year that included major impairments, weaker commercial performance and underperforming investments. He said management was acting with urgency to improve execution and strengthen long-term growth.
Buyback and Cost Savings Lift Investor Confidence
CSL announced a US$1.1 billion share buyback for FY27 after completing a US$1 billion program during FY26. Its transformation initiative has already delivered US$176 million in cost savings with a longer-term target of US$550 million.
Among its business divisions, CSL Behring generated US$11.4 billion in revenue while CSL Vifor recorded modest growth despite facing increasing generic competition for its key iron therapy. Meanwhile, vaccine business CSL Seqirus reported lower revenue due to tougher comparisons with the previous year's avian influenza-related sales.
The company maintained its annual dividend at US$2.92 per share and expects FY27 revenue to remain broadly in line with FY26 as continued growth in its core plasma business offsets expected weakness in the Vifor division.
Source: Business News Australia
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
You Might Also Like
US-UK Trade Deal Announced, but 10% Tariffs on British Exports Stay
Mastering the Art of Self-Assessment
